Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 5/2006

01-09-2006 | Original Article

Human foamy virus bel1 sequence in patients with autoimmune rheumatic diseases

Authors: Kuang-Hui Sun, Hsiao-Yi Lin, Lee-Wen Chen, Hsiao-Yun Tai, Mei-Lin Lin, Chi-Kuang Feng, Jung-Sung Sung, Hsin-Fu Liu, Wu-Tse Liu

Published in: Clinical Rheumatology | Issue 5/2006

Login to get access

Abstract

Since the association between human foamy virus (HFV) with rheumatic autoimmune diseases remains controversial, this study was designed to determine the relationship between HFV and systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or progressive systemic sclerosis (PSS). The bel1 and Pol sequences of HFV were measured by reverse transcriptase–polymerase chain reaction (RT-PCR) in plasma and by PCR in peripheral blood mononuclear cells (PBMC) from patients with SLE, RA, and PSS. Antibodies against Bel1 and Pol were assessed by enzyme-linked immunosorbent assay. Active HFV infections were detected by a Bel1-responsive indicator cell line. The bel1 sequence was detected in the plasma (SLE 59, RA 32, and PSS 63%) and PBMC (SLE 54, RA 71, and PSS 57%). However, active HFV infection existed only in patients with the bel1 sequence in both plasma and PBMC. In SLE patients, antibodies against Bel1 (7.1%) and Pol (4.5%) were also detected. The results suggest a possible association between HFV infection and these autoimmune rheumatic diseases.
Literature
1.
Herrmann M, Hagenhofer M, Kalden JR (1996) Retroviruses and systemic lupus erythematosus. Immunol Rev 152:145–156PubMedCrossRef
2.
Nakagawa K, Harrison LC (1996) The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev 152:193–236PubMedCrossRef
3.
Umovitz HB, Murphy WH (1996) Human endogenous retroviruses: nature, occurrence, and clinical implications in human diseases. Clin Microbiol Rev 9:72–99PubMed
4.
Sekigawa I, Kaneko H, Hishikawa T, Hashimoto H, Hirose S, Kaneko Y, Maruyama N (1998) HIV infection and SLE: their pathological relationship. Clin Exp Rheumatol 16:175–180PubMed
5.
Sekigawa I, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H (2001) Retroviruses and autoimmunity. Intern Med 40:80–86PubMedCrossRef
6.
Saib A, Canivet M, Giron ML, Bolgert F, Valla J, Lagaye S, Peries J, de The H (1994) Human foamy virus infection in myasthenia gravis. Lancet 343:666CrossRefPubMed
7.
Liu WT, Kaw KP, Liu YC, Chang KS (1996) Human foamy virus genome in the thymus of myasthenia gravis patients. Chin J Microbiol Immunol 29:162–165
8.
Brown P, Nemo G, Gajdusek DC (1978) Human foamy virus: further characterization, seroepidemiology and relationship to chimpanzee foamy viruses. J Infect Dis 137:421–427PubMed
9.
Bieniasz PD, Rethwilm A, Pitman R, Daniel MD, Chrystie I, McClure MO (1995) A comparative study of higher primate foamy viruses, including a new virus from a gorilla. Virology 207:217–228CrossRefPubMed
10.
McClure MO, Erlwein O (1995) Foamy viruses-pathogenesis or therapeutic potential? Rev Med Virol 5:229–237CrossRef
11.
Achong BG, Mansell PW, Epstein MA, Clifford P (1971) An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst 46:299–307PubMed
12.
Achong BG, Epstein MA (1978) Preliminary seroepidemiological studies on the human syncytial virus. J Gen Virol 40:175–181PubMedCrossRef
13.
Muller HK, Ball G, Epstein MA, Achong BG, Lenoir G, Levin A (1980) The prevalence of naturally occurring antibodies to human syncytial virus in East African populations. J Gen Virol 47:399–406PubMedCrossRef
14.
Loh PC, Matsuura F, Mitzumoto C (1988) Seroepidemiology of human syncytial virus: antibody prevalence in the Pacific. Intervirology 13:89–90
15.
Debons-Guillemin MC, Valla J, Gazeau J, Wybier-Franqui J, Giron ML, Toubert ME, Canivet M, Peries J (1992) No evidence of spumaretrovirus infection markers in 19 cases of de Quervain's thyroiditis. AIDS Res Hum Retroviruses 8:1547PubMedCrossRef
16.
Schweizer M, Turek R, Reinhardt M, Neumann-Haefelin D (1994) Absence of foamy virus DNA in Graves' disease. AIDS Res Hum Retroviruses 10:601–605PubMed
17.
Stancek D, Stancekova-Gressnerova M, Janotka M, Hnilica P, Oravec D (1975) Isolation and some serological and epidemiological data on the viruses recovered from patients with subacute thyroiditis de Quervain. Med Microbiol Immunol (Berl) 161:133–144CrossRef
18.
Werner J, Gelderblom H (1979) Isolation of foamy virus from patients with de Quervain thyroiditis. Lancet 2:258–259CrossRefPubMed
19.
Mahnke C, Kashaiya P, Rossle J, Bannert H, Levin A, Blattner WA, Dietrich M, Luande J, Lochelt M, Friedman-Kien AE (1992) Human spumavirus antibodies in sera from African patients. Arch Virol 123:245–253CrossRef
20.
Westarp ME, Fuchs D, Bartmann P, Hoff-Jorgensen R, Clausen J, Wachterm H, Kornhuber HH (1993) Amyotrophic lateral sclerosis an enigmatic disease with B-cellular and anti-retroviral immune responses. Eur J Med 2:327–332PubMed
21.
Lycke J, Svennerholm B, Svenningsson A, Muranyi W, Flügel RM, Andersen O (1994) Human spumaretrovirus antibody reactivity in multiple sclerosis. J Neurol 241:104–109CrossRef
22.
Lagaye S, Vexiau P, Morozov V, Guenebaut-Claudet V, Tobaly-Tapiero J, Canivet M, Cathelineau G, Peries J, Emanoil-Ravier R (1992) Human spumaretrovirus-related sequence in the DNA of leukocytes from patients with Graves' disease. Proc Natl Acad Sci U S A 89:10070–10074PubMedCrossRef
23.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
24.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
25.
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
26.
Tai H-Y, Sun K-H, Kung S-H, Liu W-T (2001) A quantitative assay for measuring human foamy virus using an established indicator cell line. J Virol Methods 94:155–162CrossRefPubMed
27.
Flügel RM (1992) Spumaviruses: a group of complex retroviruses. J Acquir Immune Defic Syndr 4:739–759
28.
Yu SF, Linial ML (1993) Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol 67:6618–6624PubMed
29.
He F, Blair WS, Fukushima J, Cullen BR (1996) The human foamy virus Bel-1 transcription factor is a sequence-specific DNA binding protein. J Virol 70:3902–3908PubMed
30.
Löchelt M, Muranyi W, Flügel RM (1993) Human foamy virus genome possesses an internal, bel-1 dependent and functional promoter. Proc Natl Acad Sci U S A 90:7317–7321PubMedCrossRef
31.
Löchelt M, Zentgraf HW, Flügel RM (1991) Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel1 gene. Virology 184:43–54PubMedCrossRef
32.
Bothe K, Aguzzi A, Lassmann H, Rethwilm A, Horak I (1991) Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes. Science 253:555–557PubMedCrossRef
33.
Whitton JL, Fujinami RS (1999) Viruses as triggers of autoimmunity: facts and fantasies. Curr Opin Microbiol 2:392–397PubMedCrossRef
34.
Horwitz MS, Sarvetnick N (1999) Viruses, host responses, and autoimmunity. Immunol Rev 169:241–253PubMedCrossRef
35.
Paroli M, Schiaffella E, Di Rosa F, Barnaba V (2000) Persisting viruses and autoimmunity. J Neuroimmunol 107:201–204PubMedCrossRef
36.
Shiohara T (2000) Vrial infections, allergy and autoimmunity: a complex, but fascinating link. J Dermatol Sci 22:149–151CrossRefPubMed
37.
38.
Regner M, Lambert P-H (2001) Autoimmunity through infection or immunization? Nat Immunol 2:185–188CrossRefPubMed
39.
Tamura N, Sekigawa I, Hashimoto H, Yamamoto N, Kira S (1997) Syncytial cell formation in vivo by type C retroviral particles in the systemic lupus erythematosus (SLE) lung. Clin Exp Immunol 107:474–479CrossRefPubMed
40.
Keller A, Garrett ED, Cullen BR (1992) The Bel-1 protein of human foamy virus activated human immunodeficiency virus type 1 gene expression via a novel DNA target site. J Virol 66:3946–3949PubMed
41.
Wagner A, Doerks A, Aboud M, Alonso A, Tokino T, Flugel RM, Lochelt M (2000) Induction of cellular genes is mediated by the Bel1 transactivator in foamy virus-infected human cells. J Virol 74:4441–4447CrossRefPubMed
Metadata
Title
Human foamy virus bel1 sequence in patients with autoimmune rheumatic diseases
Authors
Kuang-Hui Sun
Hsiao-Yi Lin
Lee-Wen Chen
Hsiao-Yun Tai
Mei-Lin Lin
Chi-Kuang Feng
Jung-Sung Sung
Hsin-Fu Liu
Wu-Tse Liu
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0146-5

Other articles of this Issue 5/2006

Clinical Rheumatology 5/2006 Go to the issue

Case Report

Synovial haemangioma of the knee: a case report

Original Article

Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice

Case Report

Infliximab in a child with therapy-resistant systemic vasculitis

Case Report

Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis

Case Report

Coexistence of anomalous origin of the coronary arteries and severe aortic regurgitation in Marfan syndrome

Letter to the Editor

Reply to the report: epidemiology of rheumatoid arthritis in Turkey (by N. Akkoc, S. Akar)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits